Paroxetine Hydrochloride, known by the trade name Paxil, has an upcoming patent expiration date of May 19, 2015. As a well used medication to treat depression, Paroxetine HCl, CAS number 78246-49-8, is projected to become a generic powerhouse. Paroxetine is efficacious at treating not only major depression, but also obsessive compulsive disorder, panic disorder, social anxiety disorder, generalized anxiety disorder, and post traumatic stress disorder. Offered in 10, 20, 30 and 40 milligram tablets, paroxetine is generally well tolerated among patients. Side effects of paroxetine may include sweating, dizziness, insomnia, constipation, excessive yawning, and dry mouth. Paroxetine is marketed as Paxil by GlaxoSmithKline, which has been approved by the FDA to also treat premenstrual dysphoric disorder.
LGM Pharma is a provider of the API paroxetine hydrochloride, and the TEVA API Paroxetine HCl, CAS number 78246-49-8. Clients can rely on LGM Pharma to provide complete support through the entire R&D process.
Effective as a type of selective serotonin reuptake inhibitor, or SSRI, paroxetine effects the brain chemical serotonin. As serotonin is a specific chemical used to send messages from one nerve cell to another, havoc can erupt in the brain when the levels of serotonin become unbalanced. Paroxetine can help to put an end to or at least help to control this imbalance, by blocking the reuptake of serotonin so that more serotonin remains in the space between the brain’s nerve cells. With a proper balance of serotonin the brain is able to function normally, and patients do not experience the symptoms of depression, anxiety and other related disorders. Paroxetine is used off label in some settings to treat other mental disorders, such as anorexia, alcoholism and dementia without Alzheimer’s disease.
While there has been controversy for years over the potential for adverse effects of SSRI’s, such as suicidal thoughts, especially among adolescents, paroxetine is still absolutely necessary for those patients who need it. There are also still plenty of patients, with the numbers growing each year. According to the Anxiety and Depression Association of America anxiety disorders are the most common mental illness in the U.S., affecting 40 million adults in the United States. Anxiety disorders are easily treatable, yet only one-third of those suffering from these disorders receive treatment. Nearly one-half of people diagnosed with depression are also diagnosed with an anxiety disorder as well. Other mental disorders, such as panic disorder and generalized anxiety disorder are being diagnosed in greater numbers in U.S. citizens also. Paroxetine is an excellent option for the treatment of the 6.8 million adults affected with generalized anxiety disorder, the 2.2 million Americans suffering from obsessive compulsive disorder, and the 2.7 million adults afflicted with panic disorder. For patients who receive treatment from antidepressants like paroxetine they have the opportunity to experience a much better quality of life. While SSRI’s typically take between 2 and 6 weeks to work with efficacy, patients taking paroxetine should undergo psychiatric care throughout their medication titration. Contrary to popular belief, paroxetine is not a “happy pill” which creates instant jubilation. Rather, it is an extended treatment to help aid patients suffering from chemical imbalances in their brain.
Why do some people need paroxetine or other medications for depression, anxiety and other mental disorders while others do not? The answer is complex, and is believed to be a combination of a complex set of risk factors, including genetics, brain chemistry, personality, and even life events. Mental disorders continue to plague not only Americans, but also people worldwide. There is no group of people safe from these biochemical disorders, and anyone can be affected. For example, a study released from Harvard Medical School on July 3, 2012 found that 1 in 12 American teenagers has an anger disorder. Eight percent of the adolescents have regular violent outbursts that would fall into the category of a mental health disorder. This study, which was funded by the National Institute of Mental Health, consisted of 10,000 teenagers and parents, and determined that anger disorder tends to start early in life, with signs and symptoms usually being present by age 12. Boys were also found to be three times as likely to suffer from anger disorder in comparison to girls. Study leader and Harvard epidemiologist Ronald Kessler suggested that behavioral therapy as well as treatment with an SSRI, like paroxetine would be effective and safe for the adolescent population. Statistics show that mental disorders often are related to one another.
In fact, the Harvard study found that less than 7 percent of teenagers with anger disorder were being treated for their anger, but they were receiving psychiatric help for related conditions, like depression and alcoholism. Dr. Kessler believes the aformentioned disorders may have resulted from the untreated anger condition. With the release of the DSM-V due out in 2013 there are sure to be additional conditions which paroxetine will be indicated for, as well as the large list of disorders it is already FDA approved to treat.
Products currently covered by valid US Patents are offered for R&D use in accordance with 35 USC 271(e)+A13(1). Any patent infringement and resulting liability is solely at buyer risk.